Robotic and manual platforms that transform a diagnostic endoscope into a precise surgical tool for endoluminal therapies.
Since the early 2000s, the field of endoluminal therapy has experienced explosive growth. Breakthrough procedures — such as ESD, EMR, GERD therapies, ESG, POEM, and EFTR — are revolutionizing non-invasive treatment.
Physicians still lack adequate robotic tools for complex GI procedures.
EndoRobotics fills this gap with intuitive robotic manipulation tools.
Make advanced endoscopic therapy accessible — reducing the skill barrier, procedure time, and risk of complex, minimally invasive treatment.
Empowering endoluminal therapy with intelligent robotics — making complex endoscopic procedures safer, faster, and universally accessible.
To become the most innovative leader in Robotic Endoluminal Surgery.
We believe true innovation in healthcare happens when advanced technology meets real-world clinical and economic realities. Instead of forcing hospitals to replace their existing infrastructure, EndoRobotics delivers immediate, cost-effective robotic capabilities today, while pioneering full-scale autonomous endoluminal robots for tomorrow.
Scar-free, incisionless therapy that shortens recovery and lowers the risk of open or laparoscopic surgery.
We lower the steep learning curve of ESD, ESG and closure so more clinicians can offer these procedures.
Our platforms are developed with clinicians and supported by peer-reviewed, first-in-human evidence.
A robotic platform, single-use therapeutic devices, and a training simulator — engineered to work together.
ROBOPERA™ is the robotic driver platform at the core of the system, powering compatible instruments and controllers for endoscopic procedures.
ROBOPERA™
TraCloser™ provides precise tissue traction to support complex endoscopic procedures.
TraCloser™
EndoCubot™ is a non-medical simulator for realistic, multi-procedure endoscopy training.
EndoCubot™A single, standardized controller powers our entire suite of therapeutic tools, streamlining OR setup and reducing operational complexity.
Whether performing ESD, EMR, or complex defect closures, surgeons can snap on specialized single-use manipulators tailored to specific clinical indications.
All manipulator tools are procedure-specific single-use consumables, supporting high standards of patient safety and sterility.
Founded on 20+ years of interdisciplinary research, EndoRobotics was spun out from a collaborative team of Mechanical Engineering researchers at Korea University and gastroenterologists at Korea University Hospital, formed to address the growing endoluminal therapy market. Our founding vision and technical architecture have since been validated by clinical experts, key opinion leaders, and industry partners — and supported by regulatory approvals from Korea's MFDS and FDA clearance for our core robotic platform in the U.S.
Founded in Seoul (April 2019) as a Korea University spin-off by six robotics and clinical experts.
Raised a KRW 4.85 billion Series A round to advance the RoSE robotic platform.
Closed a Series B round of approximately KRW 10 billion, bringing cumulative investment toward KRW 20 billion.
The RoSE endoscopic robotic platform is selected among the year's leading mechanical technologies.
Made its global debut at DDW 2024 (Washington, D.C.) and went on to present at APDW, UEG Week and ENDO 2024.
Robotic traction-and-closure technique for colorectal ESD reported in the peer-reviewed literature (VideoGIE).
Demonstrated the platform in an international joint live endoscopy broadcast.
ROBOPERA™ receives manufacturing approval from Korea's Ministry of Food and Drug Safety (MFDS).
EndoCubot™ obtains KC, FCC and CE certifications (December 2024).
ROBOPERA™ with the TraCloser™ robotic gripper receives FDA 510(k) clearance (September 2025).
Closed a KRW 32.5 billion Series C round (December 2025) at a pre-money valuation of about KRW 120 billion.
A first-in-human robotic ESD pilot study is published in Gastrointestinal Endoscopy.
The only Korean company invited alongside Intuitive Surgical, Medtronic and Boston Scientific (Cedars-Sinai, Los Angeles).
Signed an exclusive global distribution agreement with Olympus, announced at DDW 2026 (May 2026), adding its robot-assisted technologies to Olympus' EndoTherapy portfolio.
We started EndoRobotics to make advanced, incisionless endoscopic therapy something every clinician can offer — turning a standard endoscope into a precise surgical robot.
— The founders of EndoRobotics —
Professor of Mechanical Engineering, Korea University · 30+ years in robotics research.
Research Professor of Mechanical Engineering, Korea University · robotics & medical device development.
We're always looking for people who want to help build the future of endoscopic therapy — see our open roles or reach out to our team.
Contact us
The Challenge